The United Kingdom and the United States have secured a significant bilateral deal that will guarantee zero import taxes on British pharmaceutical exports being sold in the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise spending on drugs through the National Health Service (NHS). This commitment secures that tariffs on these vital products will be held at nothing for a duration of 36 months.
This deal comes after recent statements to significantly raise tariffs on patented pharmaceutical products, with potential rates floated as high as one hundred percent.
"This arrangement with the United Kingdom strengthens the global environment for new treatments and establishes much-needed equity to American-British pharmaceutical trade," a statement said.
Commercial Impact
Medicines are one of the the United Kingdom's biggest export categories to the US, which is clearly the largest buyer for major companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months prior to last September, the UK sold medicines worth billions to the US. This amount represented a significant portion of total UK exports in that timeframe.
"This agreement secures work, increases funding and facilitates the UK to emerge as a worldwide center for medical research," a minister stated.
Detailed UK Commitments
The agreement entails several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to increase overall public funding on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must refund to the NHS to control costs will be limited at 15%. Previously, repayments were more than 20%.
Recent Tensions
The deal follows a long-running row between the pharmaceutical industry and the UK government over spending levels and approval rates.
This friction were heightened by arguments that US patients were charged a premium for the identical medicines than patients in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been paused or abandoned, while major expansions have been pledged toward US facilities.
The Science Minister stated that the NHS had to increase expenditure on drugs, noting that its spending on drugs had shrunk as a percentage of its overall budget over the past decade.
